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Available online 28 September 2016Background: Plasma lipid disorders are key risk factors for the development of atherosclerotic cardiovascular disease
(ASCVD) and are prevalent in the Middle East, with rates increasing in recent decades. Despite this, no region-
speciﬁc guidelines formanagingplasma lipids exist and there is a lackof use of guidelines developed in other regions.
Methods: A multidisciplinary panel of regional experts was convened to develop consensus clinical recommenda-
tions for themanagement of plasma lipids in theMiddle East. The panel considered existing international guidelines
and regional clinical experience to develop recommendations.
Results: The panel's recommendations include plasma lipid screening, ASCVD risk calculation and treatment consid-
erations. The panel recommend that plasma lipid levels should bemeasured in all at-risk patients and at regular in-
tervals in all adults from the age of 20 years. A scoring system should be used to calculate ASCVD risk that includes
known lipid and non-lipid risk factors. Primary treatment targets include low-density lipoprotein cholesterol and
non-high-density lipoprotein cholesterol. Lifestyle modiﬁcations should be ﬁrst-line treatment for all patients; the
ﬁrst-line pharmacological treatment targeting plasma lipids in patients at moderate-to-high risk of ASCVD is statin
therapy,with a number of adjunctive or second-line agents available. Guidance is also provided on themanagement
of underlying conditions and special populations; of particular pertinence in the region are familial hypercholester-
olaemia, diabetes and metabolic dyslipidaemia.
Conclusions: These consensus clinical recommendations provide practicing clinicians with comprehensive, region-
speciﬁc guidance to improve the detection andmanagement of plasma lipid disorders in patients in theMiddle East.
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269N. Al Sayed et al. / International Journal of Cardiology 225 (2016) 268–2831. BackgroundDisorders of plasma lipids are key risk factors for the development of
atherosclerotic cardiovascular disease (ASCVD) [1,2], which is a leading
cause of morbidity and mortality worldwide [3]. Typical disorders of
plasma lipids include elevated levels of low-density lipoprotein
cholesterol (LDL-C), elevated non-high-density lipoprotein cholesterol
(non-HDL-C), elevated plasma triglyceride (TG), and low levels of
high-density lipoprotein cholesterol (HDL-C) [1]. These plasma lipid
disorders may be primary, occurring due to the interaction of genetic
susceptibility and environmental risk factors or secondary [4,5], occur-
ring as a result of other disorders (e.g. diabetes, hypothyroidism, ne-
phrotic syndrome) [5–7].
Disorders of plasma lipids are awell-known problem in theWestern
world [8], and are an issue of increasing importance in the Middle East.
Although estimates are hampered by a lack of clinical studies in the re-
gion and by inconsistencies in the deﬁnitions and thresholds used in
those studies that have been conducted, the prevalence of plasma
lipid disorders in the region is high [9]. Available data vary in their esti-
mates [10–16], with prevalence as high as 50% or more in some areas. A
literature review assessing the prevalence of plasma lipid disorders in
Gulf countries, using studies published from 1987 to 2010, found that
reported rates ranged from 3% to 52% across varying population types
[10]. Similarly a further study of hypercholesterolaemia in the Gulf re-
gion, evaluating data from 1990 to 2014, found the prevalence range
to be 17–55% in males and 9–54% in females [11]. A large (n = 4378)
study in the Middle East and Africa found that 70% of stable outpatients
who attended general practice clinics had disorders of plasma lipids; in
all countries in the study, the prevalence of these disorders in this pop-
ulation was N50% [16]. Of these, only 16% of subjects were receiving
lipid-lowering medications and many subjects were not achieving
LDL-C goals recommended in international guidelines [16]. Large
(n N 6000) prospective registries of patients with acute coronary syn-
drome conducted in Gulf countries (GULF RACE and GULF RACE-2) esti-
mated the prevalence of plasma lipid disorders to be 31–32% [12,13].
In addition to these high prevalence rates, the proﬁle of plasma lipid
disorders observed in the Middle Eastern population differs somewhat
to that seen in many other regions, with metabolic dyslipidaemia
(high TG, low HDL-C and high or normal LDL-C) being one of the most
common types [9]. The presentation of high TG and low HDL-C levels
has also been observed amongpatients in the regionwhoare already re-
ceiving chronic statin treatment; the DYSIS Middle East study (n =
2182) found that 62% still have high LDL-C levels, 56% have low HDL-C
levels, and 49% have high TG levels [17]. A number of key risk factors
formetabolic dyslipidaemia are common among the population, includ-
ing type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS)
[9]. There is also a high prevalence of heterozygous and homozygous fa-
milial hypercholesterolaemia (FH), possibly secondary to a high preva-
lence of consanguineousmarriages [9]. The prevalence of many of these
factors has increased in the region over recent decades [18,19]. A further
characteristic of the Middle Eastern population is an earlier onset of
ASCVD compared with populations in Western countries. The
INTERHEART study, a case-control study conducted in 52 countries,
found that theMiddle East has the lowest average age to ﬁrst myocardi-
al infarction (51 years) [20].
International guidelines exist and all agree on most key recommen-
dations [2,4,5,21], however there is lack of awareness and adherence to
these international guidelines by local healthcare professionals [9]. This
paper aims to provide practical recommendations for the management
of plasma lipid disorders, speciﬁcally forMiddle Eastern populations [9].
1.1. Aim
A multidisciplinary panel of regional experts in plasma lipid disor-
ders was convened with the aim of developing consensus clinical rec-
ommendations for themanagement of plasma lipids in theMiddle East.The panel considered a number of existing international guidelines,
including:
• American College of Cardiology (ACC)/American Heart Association
(AHA): Guideline on the Treatment of Blood Cholesterol to Reduce
Atherosclerotic Cardiovascular Risk in Adults. 2013 [5].
• European Society of Cardiology (ESC)/European Atherosclerosis Society
(EAS): Guidelines for the Management of Dyslipidaemias. 2011 [4].
• International Atherosclerosis Society (IAS): Global Recommendations
for the Management of Dyslipidemia. 2013 [21].
• National Lipid Association: Recommendations for Patient-Centered
Management of Dyslipidemia. 2015 [2,22].
• Kidney Disease Improving Global Outcomes (KDIGO): KDIGO Clinical
Practice Guideline for Lipid Management in Chronic Kidney Disease.
2013 [23].
• American Association of Clinical Endocrinologists (AACE): Guidelines for
Management of Dyslipidemia and Prevention of Atherosclerosis. 2012
[24].
There is a high degree of agreement in the recommendations
proposed in these international guidelines. In cases where the inter-
national guidelines disagreed, or did not make speciﬁc recommenda-
tions of relevance to the Middle East, the panel came to consensus
based on comprehensive literature searches and regional clinical
experience.
The recommendations from the panel are detailed in the following
sections.2. Screening
Screening for plasma lipid disorders should be performed in all pa-
tients with T2DM [4,22], evidence of ASCVD [4,22], arterial hyperten-
sion [4], central obesity [4], chronic inﬂammatory autoimmune
disease [4], chronic kidney disease (CKD) [4,22], a family history of
ASCVD, and in the offspring of patients with severe disorders of plasma
lipids (e.g. FH) [4] (Box 1). These patients are considered to be at high
risk for plasma lipid disorders and the development of ASCVD. Screen-
ing should also be considered in all adults ≥20 years old and should be
repeated every ﬁve years [22].2.1. Screening endpoints
2.1.1. Assessment of lipids
Screening should include the measurement of lipid levels including
LDL-C, plasma total cholesterol (TC), TG, HDL-C and non-HDL-C. Either
fasting [4] or non-fasting [22,25] measurements may be used.
Directmethods for measuring LDL-C should be used if available. Cal-
culation of LDL-C is also possible using Friedewald's formulae, although
this method is subject to a number of assumptions and limitations and
cannot be used if TG levels are high [4].
Measurement of non-HDL-C provides an estimate of the concentra-
tion of cholesterol in all atherogenic lipoproteins in the plasma (very
low-density lipoprotein [VLDL], intermediate-density lipoprotein and
LDL). Non-HDL-C is calculated by subtracting HDL-C levels from plasma
TC levels [4,21,22]. Commercially available assays should be used for
measuring HDL-C, TC and TG levels, including assay validation with ref-
erence and control agents [4].
Elevated plasma lipoprotein(a) (Lp(a)) levels are also indicative of
an increased ASCVD risk [4,26,27] and elevated levels require a speciﬁc
treatment approach (see Section 7.2). Therefore, measurement of
Lp(a) should be considered in high-risk patients [4]. Lp(a) can be mea-
sured using a commercially available, size-insensitive assay – it is im-
portant to ensure assay standardisation [4].
Box 1
Patient populations recommended for plasma lipid screening
• Once every five years in patients≥20 years old [22,24]
• T2DM [4,22]
• Arterial hypertension [4]
• Manifest ASCVD [4,22]
• Central obesity [4]
• Chronic inflammatory autoimmune disease [4]
• CKD [4,22]
• Family history of ASCVD [4]
• Offspring of patients with severe disorders of plasma lipids (e.g.
FH) [4]
ASCVD, atherosclerotic cardiovascular disease; CKD, chronic
kidney disease; FH, familial hypercholesterolaemia; T2DM,
type 2 diabetes mellitus
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A number of plasma lipid disorders, such as FH, familial combined
hyperlipidaemia (FCHL), dysbetalipoproteinaemia [4] and hypertri-
glyceridaemia [28] have genetic components. Assessment of family
history is therefore an integral part of diagnosis and the panel recom-
mend that genetic testingmay be considered, although data are current-
ly somewhat limited in this regard.
There are currently no consensuses among guidelines for the diag-
nosis of FH and different criteria exist to diagnose FH cases, including
the use of biochemical, clinical, genetic and radiological investigations.
Nevertheless, genetic testing should be considered in families with FH
[4]. Elevated LDL-C in FH is present from birth and there is evidence
that the prognosis of both heterozygous and homozygous FH is im-
proved with early treatment [4]. Detection of FH via clinical assessment
alone can be particularly challenging in patients where LDL-C elevation
is less marked [29] and the CVD risk levels of patients with FH may not
accurately be predicted by the use of multivariate risk scoring (see
Section 3) [4]. Therefore, genetic screening should be considered to
identify common mutations causing FH in the region for new-borns
with LDL-C elevation or clinical signs suggestive of FH. This genetic con-
ﬁrmation, which could be incorporated into the analysis of the blood
sample taken in the new-born heel prick test, may help to differentiate
FH from FCHL and polygenic hypercholesterolemia with increased
Lp(a). A systematic literature review identiﬁed 57mutations in theMid-
dle East and North Africa [30]; Table 1 summarises those reported in
Middle Eastern countries. To date, the availability and uptake of genetic
testing for FH in the Middle East has been limited [29].
3. Calculation of CVD risk
3.1. Estimating CVD risk
Assessment of ASCVD risk should take account of both lipid and non-
lipid risk factors [2,4,24]. A number of patient groups shouldTable 1
FH-related genetic mutations reported in the Middle East.
Country Reported FH-related mutations
Bahrain LDLR c.1706-2ANT [30]
Iran LDLR c.1478_1479delCT or LDLR c.1476_1478delCT (FH-Yrmeih); LDLRA
Lebanon LDLRAP1 c.406CNT; LDLRAP1 p.P202H/ LDLRAP1 c.747+744GNA; LDLR
LDLR p.Q254P; LDLR p.D356Y; LDLR p.C358Y; LDLR c.1329GNA; LDLR p.I45
[30]; PCSK9 L21dup [30]
Oman LDLR c.272delG; PCSK9 p.V474I [30]
Saudi Arabia LDLR c.2439GNA [30], p.W813* [33]; LDLR c.2027delG, p.(G676Afs*33) [34]
p.P105S [37]; LDLR c.498CNT, p.A166 = [37]; LDLR c.1171GNA, p.A391T [37
Syria LDLR c.2043CNA [30]; LDLR p.C667R [30]; LDLR c.1999TNC, p.C646R [38];automatically be considered to be at high or very high risk of developing
ASCVD, and should receive pharmacological therapy targeting plasma
lipids. These include patients with known ASCVD [2,4,21,22], FH (due
to a high risk of premature ASCVD, in absence of other risk factors) [4,
21,29], T2DM [2,4,21,22] and CKD [2,4,21,22]. For other patients outside
of these high-risk groups, the patient's global risk of ASCVD should be
estimated using a scoring system (see Section 3.2) [4].3.2. Key scoring systems
Anumber of different ASCVD risk scoring systems are recommended
in existing international guidelines. Some scoring systems permit the
calculation of lifetime CVD risk, while others calculate 10-year risk. Life-
time risk calculations may be of greater clinical relevance in the Middle
East, due to the earlier onset of ASCVD in this population. Whichever
scoring system is used, it should be remembered that ASCVD risk exists
on a continuum, with thresholds for risk classiﬁcation being somewhat
arbitrary [4].3.2.1. Ethnicity and scoring systems
Of the available scoring systems, the Framingham Risk Factor (FRF)
has been assessed most widely in different ethnic groups, including in
Middle Eastern populations, and is discussed in Section 3.2.2. The
QRISK2 [40] also includes adjustment for ethnicity and has been com-
pared with the FRF in an ethnically diverse UK population. One study
found both systems to underestimate ASCVD risk in SouthAsian females
[41], while another found the QRISK2 to underestimate ASCVD risk in
South Asian males [42]. The SCORE risk chart, developed for European
countries, has both a low- and high-risk version for use in different
countries in the region, but the high-risk version may still underesti-
mate risk in some Eastern European and Central Asian countries [43].
The Reynolds Risk Score,which incorporatesmeasurement of additional
risk factors such as levels of high-sensitivity C-reactive protein, was de-
veloped and validated usingdata from24,558 initially healthy American
women who were followed over a 10-year period for the development
of heart attack, stroke, angioplasty (balloon surgery to open an artery),
coronary artery bypass surgery, or death related to heart disease [44].
The Reynolds Risk Score for men was similarly developed using data
from 10,724 initially healthy non-diabetic American men [45]. Howev-
er, the score has since been examined in a US race-balanced, multi-
ethnic (white African American, Hispanic and Chinese participants)
population study and found to be predictive of ASCVD risk in males,
but to underestimate risk in females [46]. However, a further study
comparing the Reynolds Risk Score with the FRF in a multi-ethnic fe-
male population found the Reynolds Score to be better calibrated and
to better discriminate between black and white females [47]. In 2013,
the ACC/AHA published race-speciﬁc algorithms for the calculation of
10-year and lifetime CVD risk in non-Hispanic African American and
white populations and recommended that the non-Hispanic white
population version of the algorithms be used in other ethnic groups
[48].P1 c.71dupG; LDLR 2140+5GNA; LDLR 1773CNT; LDLR 1413GNA; LDLR 1725CNT [30]
AP1 c.89-1GNC; LDLRAP1 c.748-608GNA [30], p.W249ins62* [31]; LDLR c.2043CNA;
1T; LDLR p.P826S; LDLR p.T726I [30]; LDLRc.1171GNA, p.A391T [30,32]; LDLR c.980dupA
; LDLR c.2026delG, p.(G676Afs*33) [35]; LDLR c.1332dup, p.(D445*) [36]; LDLR c.313CNT,
]
LDLR c.1027GNA, p.G343S [39]; LDLR c.2483ANG, p.Y828C [39]; LDLRAP1 c.89-1GNC [30]
Box 3
Classifications of cholesterol and triglyceride levels [22].
Lipid levels (mmol/L) Lipid levels (mg/dL) Classification
Non–HDL-C
3.4 b130 Desirable
3.4–4.1 130–159 Above desirable
4.1–4.9 160–189 Borderline high
4.9–5.7 190–219 High
N5.7 ≥220 Very high
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The Framingham ASCVD risk calculator (Framingham Risk Factor) is
widely established and is commonly cited in existing international
guidelines [4,21,22]. It incorporates various factors (Box 2) into multi-
variable sex-speciﬁc algorithms for the prediction of ﬁrst cardiovascular
(CV) event in patients [49].
This calculator is predictive of general ASCVD risk, rather than a spe-
ciﬁc disorder, thereby increasing utility in primary care and optimising
ease of use for primary care physicians [49]. Two versions exist that ei-
ther incorporate laboratory parameters (i.e. lipid levels) or replace these
with inclusion of the patient's bodymass index (BMI) (ofﬁce-based ver-
sion). The ofﬁce-based version of this scoring systemmay have particu-
lar practical value in developing countries [51].
The FRF has its drawbacks, however. Limitations include a lack of TG
level assessment [21] (high levels of TGs are a common feature of plas-
ma lipid disorders in the Middle East) and limited predictive value in
CKD patients [52]. In addition, the FRF calculates 10-year risk rather
than lifetime risk. As mentioned in Section 3.2, lifetime risk calculations
may be of greater clinical relevance in the Middle East. This means that
clinicians may wish to choose an alternative scoring system, depending
on the speciﬁc needs of their clinic.
Nevertheless, an advantage of the FRF is that validation and recali-
bration studies have been conducted in Middle Eastern populations. A
Turkish study of patients undergoing coronary angiography for the as-
sessment of coronary artery disease (CAD) due to chest pain and ischae-
mia (n = 227), found that a FRF score calculated before angiography
was in general predictive of the presence, extent and severity of CAD.
The score was more predictive in patients with hypertension, obesity
or a family history of the disorder and less predictive in male patients
and in those with diabetes [53]. A large Iranian study (n= 46,674) re-
ported the performance of the ofﬁce-based version of the FRF in
predicting fatal CVD events to be comparable with that of previously
tested models [51]. A further Iranian study (n= 6224) also conﬁrmed
clinical utility in this country's population, concluding that it may be
more useful in males than in females [54].
Overall, it should be remembered that no scoring system is perfect
for estimating ASCVD risk. Nonetheless, the use of a scoring system is
important for approximating a patient's ASCVD risk and the need for
pharmacological therapy. In this regard healthcare professionals in the
Middle East may select those that they feel most appropriate to their
own clinical practice. If healthcare professionals are unsure as to
which scoring system is most appropriate for their clinic, then the FRF
is a reasonable choice.LDL-C
b2.6 b100 Desirable
2.6–3.3 100–129 Above desirable
3.3–4.1 130–159 Borderline high
4.1–4.9 160–189 High
N4.9 ≥190 Very high3.3. Other considerations when estimating CVD risk
Family history is an important component of ASCVD risk and should
be assessed in all patients [2], in particular to identify the risk of hetero-
zygous and homozygous FH [4]. This is of particular importance in theBox 2
Factors incorporated into the Framingham 10-year ASCVD risk calcula-
tor [49,50].
• Sex (M/F)
• Age (years)
• Systolic blood pressure (mmHg)
• Treatment for hypertension (Y/N)
• Current smoker (Y/N)
• Diabetes (Y/N)
• HDL-C level (mg/dL)
• TC level (mg/dL)
HDL-C, high-density lipoprotein cholesterol; TC, total cholesterolMiddle Eastern population, where both forms of FH have an increased
prevalence [29,55] and are underdiagnosed [29,55].
Women are at increased risk for some ASCVD risk factors (e.g. diabe-
tes [4]), yet are generally under-managed in theMiddle East and under-
represented in clinical trials [2,4]. It is important to initiate ASCVD risk
assessment and subsequent treatment for dyslipidaemia in all eligible
patients, regardless of gender.
4. Treatment goals
Risk levels for ASCVD should be used to inform treatment targets,
treatment goals and treatment selection in patients with disorders of
plasma lipids [4,5,22]. Pharmacological interventions should be initiated
in all patientswith amoderate or high risk of anASCVD event. The treat-
ment goals for these patients are outlined below.
4.1. Primary treatment target: LDL-C
High LDL-C levels (Box 3) are an independent predictor of ASCVD
events [56], with risk being directly proportional to the level of LDL-C
[57,58]. Reduction of LDL-C levels reduces the risk of having an ASCVD
event [4,57]. The importance of reducing LDL-C levels is highlighted by
the well-documented effects of statin therapy, with a number of pivotal
clinical trials conﬁrming that statin treatment reduces ASCVD risk [59–
67]. Further evidence for the importance of LDL-C as a treatment target
exists in the markedly increased ASCVD risk associated with FH [68].
A meta-analysis of clinical trials of statin therapy concluded that for
every 1.0 mmol/L reduction in LDL-C there is an approximate 20% de-
crease in the risk of having amajor ASCVD event. The authors of this anal-
ysis recommended that LDL-C goals should therefore exceed the one-
third reduction that is currently commonly used in clinical practice [69].HDL-C
b1.0 b40 (males) Low
b1.3 b50 (females) Low
TG
b1.7 b150 Normal
1.7–2.2 150–199 Borderline high
2.2–5.6 200–499 High
N5.6 ≥500 Very high
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipopro-
tein cholesterol; TG, triglyceride.
Reprinted from J Clin Lipidol, Vol 9, Jacobson et al. National Lipid Associ-
ation recommendations for patient-centered management of dyslipid-
emia: Part 1—full report, pp. 129–169, Copyright (2015), with
permission from Elsevier.
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The ESC/EAS [4] and the IAS [21] guidelines recommend that, in
high-risk patients, LDL-lowering therapy should be used to achieve an
LDL-C b 1.8 mmol/L (b70 mg/dL). The ACC/AHA guidelines [5] recom-
mend the use of high-intensity statin therapy to reduce LDL-C by
N50%, with consideration of an adjunctive non-statin therapy to further
reduce LDL-C if required [70].We recommend that clinicians should aim
for BOTH a 50% reduction in LDL-C levels (initial goal) AND an LDL-C b
1.8 mmol/L (b70 mg/dL) (after 50% reduction is achieved) in high-risk
patients (Box 4). Clinicians should initially aim to reduce a patient's
LDL-C by 50%. If after that goal is reached the patient has levels above
1.8mmol/L (b70mg/dL), then furthermanagement is needed to reduce
this level until it is below this LDL-C goal.4.1.2. Moderate risk patients
The ESC/EAS [4] and the IAS [21] guidelines recommend LDL-
lowering therapy to achieve an LDL-C b 2.6mmol/L (b100mg/dL) in pa-
tients at moderate risk of developing ASCVD. The ACC/AHA guidelines
[5] recommend the use of moderate-intensity statin therapy to reduce
LDL-C by N30%%, with consideration of an adjunctive non-statin therapy
to further reduce LDL-C if required [70]. We recommend that clinicians
should aim for BOTH a 30% reduction in LDL-C (initial goal) AND an LDL-
C b 2.6 mmol/L (b100 mg/dL) (after 30% reduction achieved) (Box 4).4.2. Primary treatment target: non-HDL-C levels
A number of authors and international guidelines report non-HDL-C
levels (Box 3) to be more predictive of ASCVD risk than are LDL-C levels
[4,21,22,72]. Several international guidelines have recommended non-
HDL-C as a co-primary treatment target [4,21,22]. Reductions in non-
HDL-C levels by a range of lipid-lowering drug classes are associated
with decreased ASCVD events, with an approximately 1:1 relationship
between non–HDL-C decrease (%) and coronary heart disease reduction
[73]. Non-HDL-C levels are a particularly useful measure in people with
hypertriglyceridaemia, diabetes, CKD or MetS, where this value may
provide a more accurate indication of ASCVD risk than is provided by
the level of LDL-C alone [4]. Non-HDL-C levels may be of particular clin-
ical relevance in Middle Eastern populations. We therefore recommend
non-HDL-C as a primary treatment target, alongside LDL-C. Treatment
goals should be non-HDL-C levels 0.8 mmol/L (30 mg/dL) higher than
LDL-C targets for all patients [4] (Box 4).4.3. Secondary treatment targets
In terms of secondary treatment goals, clinicians should consider
HDL-C and plasma TG [4,21].Box 4
Plasma lipid treatment goals.
Primary treatment goal: LDL-C
High-risk patients
• A50% reduction (initial goal) AND b1.8mmol/L (b70mg/dL)
(after 50% reduction achieved)
Moderate-risk patients
• A 30% reduction (initial goal) AND b2.6 mmol/L (b100 mg/
dL) (after 30% reduction achieved)
Primary treatment goal: Non-HDL-C
• 0.8 mmol/L (30 mg/dL) higher than LDL-C target [4,71]
HDL, high-density lipoprotein; LDL-C, low-density lipoprotein; TG,
triglyceride.4.3.1. HDL-C
There is long-standing, well-documented and robust evidence
showing that the concentration of HDL-C is an independent inverse pre-
dictor of the risk of having anASCVD event [74]. The risk associatedwith
a low level of HDL-C (Box 3) remains apparent even when the level of
LDL-C has been reduced to low levels by treatment with a statin [75].
Furthermore, increasing the concentration of HDLs in mice and rabbits,
whether by intravenous infusions of HDLs or by overexpressing the
main HDL apolipoprotein, apoA-I, markedly decreases susceptibility to
atherosclerosis in these animals [76,77]. However, despite these consis-
tent observations, there is still no ﬁrm evidence in humans that inter-
ventions designed to increase the concentration of HDLs translate into
a reduced risk of having a clinical ASCVD event [78].
Overall, the evidence base for targeting HDL-C to prevent ASCVD is
not sufﬁcient to recommendHDL-raising therapy as a strategy to reduce
ASCVD risk. Rather, given that the presence of a low level of HDL-C is as-
sociatedwith a high ASCVD risk, it should be considered as an indication
for more aggressive LDL-C lowering therapy to reduce this risk.
4.3.2. Plasma TG
An elevated level of plasma TG (Box 3) has been shown in several
population studies to be associated with an increased ASCVD risk [79].
ESC and AACE guidelines report levels of b150 mg/dL (1.7 mmol/L) to
be desirable [4,24], and the ESC recommends that pharmacotherapy is
considered in high-risk patients with levels N200 mg/dL (2.3 mmol/L),
if lifestylemodiﬁcations are not successful alone [4]. AACE guidelines re-
port patients with TG levels ≥200 mg/dL to have a greatly increased
ASCVD risk [24]. Very high levels (N 880 mg/dL [10 mmol/L]) of plasma
TG are associated with acute pancreatitis [4]. It should be emphasised,
however, that there is still no robust, consistent evidence that reducing
the level of plasma TG translates into a reduction in ASCVD risk. As with
a low level of HDL-C, an elevated plasma TG is associated with an in-
creased ASCVD risk [80]. As a consequence, the presence of an elevated
plasma TG should be considered as an indication for more aggressive
LDL-C lowering therapy to reduce this risk. It should be noted that sub-
group analyses of several trials with ﬁbrates have provided a consistent
ﬁnding that having an elevated plasma TG level identiﬁes people who
have a signiﬁcant reduction in ASCVD risk when treated with a ﬁbrate
[81,82]. It is not known whether the reduction in risk is a consequence
of a ﬁbrate-induced reduction in plasma TG level or whether the
presence of an elevated TG identiﬁes people in whom a ﬁbrate reduces
risk by some other (unknown) mechanism. Despite the absence of
direct evidence and despite uncertainty of what level of plasma TG
should be aimed for, we recommend reducing elevated plasma TG
levels as a secondary treatment goal. We recommend that a TG level N
200 mg/dL (2.3 mmol/L) warrants treatment.
5. Pharmacological treatment of plasma lipid disorders
5.1. General principles
The initiation of pharmacotherapy for the management of plasma
lipids should be underpinned by patient education regarding the poten-
tial beneﬁts and side effects of such therapy, the importance of long-
term adherence to therapy, and the treatment goals to be achieved
[22]. Following initiation, ongoingmonitoring is important in all patient
groups, and should include the assessment of lipid levels and adherence
to both lifestyle advice and pharmacotherapy [5,22].
5.2. First-line treatment of plasma lipid disorders
Due to their proven beneﬁts in reducing both fatal and non-fatal
ASCVD events in large clinical outcome trials, statins (3-hydroxy-3-
methylglutaryl-coenzyme A [HMG-CoA] reductase inhibitors [83])
should be considered the ﬁrst-line pharmacotherapy for lowering levels
of LDL-C to reduce ASCVD risk [4,5,21,22]. The use of statins has been
Table 3
Selecting a statin based on LDL-C treatment goalsa [22].
High-intensity daily dosage ↓
LDL-C ≥ 50%
Moderate-intensity daily dosage ↓
LDL-C 30% to b50%
Atorvastatin, 40–80 mg
Rosuvastatin, 20–40 mg
Atorvastatin, 10–20 mg
Fluvastatin, 40 mg bid
Fluvastatin XL, 80 mg
Lovastatin, 40 mg
Pitavastatin, 2–4 mg
Pravastatin, 40–80 mg
Rosuvastatin, 5–10 mg
Simvastatin, 20–40 mg
bid, twice daily; LDL-C, low-density lipoprotein cholesterol.
a Individual responses to statin therapy should be expected to vary in clinical
practice. Moderate- or high-intensity statin therapy is preferred unless not
tolerated. Reprinted from J Clin Lipidol, Vol 9, Jacobson et al. National Lipid As-
sociation recommendations for patient-centeredmanagement of dyslipidemia:
Part 1—full report, pp. 129–-169, Copyright (2015), with permission from
Elsevier.
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patients in the Middle East revealed that the majority of high-risk pa-
tients requiring high intensity lipid lowering therapywere not receiving
treatment that would enable them to meet the recommended target
LDL-C reduction [84–86]. This contrasts with ﬁndings from Europe,
which show that statin use has increased steadily over the past decade
in both high-risk (i.e. Sicily) and low-risk (e.g. Stockholm) regions [87].
Nevertheless, even in Europe, a recent study showed that a sizeable por-
tion of high-risk patients receiving lipid-lowering medication fail to
achieve LDL-C target reduction and require more intensive lipid man-
agement [88].
The choice of statin should be based on the lipid-lowering target of
the patient [4] (Table 3), statin–drug interactions (cytochromepathway
statins) and underlying renal function. If themaximum tolerated dose is
not efﬁcacious, then an alternative, more potent statin should be used.
If, after switching, the treatment goal is still not achieved then another
pharmacological agent should be added [4,5,22] (see Section 4.3),
after ﬁrst assessing patient adherence to treatment (including to life-
style modiﬁcations) [5]. Statins are generally well tolerated, with seri-
ous side effects a rare occurrence. The most clinically important
adverse effect associated with statin treatment is myopathy (occurring
in b1/1000 patients), which, in rare cases, can lead to rhabdomyolysis
and subsequent renal failure. Statin-induced myopathy can be mea-
sured via creatine phosphokinase (CK) levels, with an increase of ﬁve
to ten times the upper limit of normal (ULN), measured on two occa-
sions, requiring further evaluation [4,100] and levels greater than ten
times the ULN suggesting myopathy [100]. Myalgia without CK eleva-
tion can occur in 5–10% of patients [4]. Dose-dependent increases in he-
patic transaminases also occur in 0.5–2% of statin patients, although
statin-induced liver failure is extremely rare [4]. If hepatic transami-
nases are more than three times the ULN on two occasions a few days
or weeks apart, consideration should be given to reducing the dose of
the statin or even stopping the statin and using an alternate LDL-
lowering therapy. If a patient is found to be truly intolerant to statin
therapy, this indicates a switch to an alternative pharmacotherapy
(see below) [22,70].5.3. Add-on, or second-line therapy to manage plasma lipids
Several classes of LDL-lowering agents are available as add-on ther-
apy to statins – or as second-line therapy in cases of statin intolerance
[4,21,70]. These include cholesterol absorption inhibitors, bile acid
sequestrants, niacin and proprotein convertase subtilisin/kexin type 9
(PCSK9) inhibitors (Table 2).Table 2
The effects of currently available drug classes on low-density lipoprotein cholesterol levels
when used for the general management of dyslipidaemia.
Pharmacological class Reported decrease in LDL-C levels
Statins 25–55% [21]
Cholesterol absorption
inhibitors (ezetimibe)
15–20% as monotherapy [4]
Addition to a statin: 15–20% further reduction, beyond
statin alone [89]
Bile acid sequestrants 18–25% as monotherapy [4]
Addition to a statin: 10–20% further reduction, beyond
statin alone [4]
Niacin 15–18% as a monotherapy [4]
Addition to a statin/ezetimibe: 38% further reduction,
beyond statin/ezetimibe combination alone [90]
PCSK9 inhibitors 47–57% as monotherapy [91–94]
Addition to a statin/ezetimibe: 44–75% further
reduction, beyond statin or ezetimibe alone [4,93,95–99]
LDL-C, low-density lipoprotein cholesterol; PCSK9, proprotein convertase subtilisin/kexin
type5.3.1. Cholesterol absorption inhibitors
The cholesterol absorption inhibitor, ezetimibe, has been used both
as add-on therapy to statins and as monotherapy in cases of statin intol-
erance [4,21].When used as amonotherapy, ezetimibe reduces LDL-C by
15–20% [4]. When added to a statin, ezetimibe provides an average
15–20% further reduction in LDL-C, beyond that of the statin alone [89]
(Table 2). Addition of ezetimibe to a statin reduces ASCVD events (IM-
PROVE-IT trial) [101,102]; this indication is now approved in Europe
[103,104], although the US Food and Drug Administration (FDA) did
not approve a proposed label change based on these ﬁndings [105]. A re-
cent consensus document from the ACC suggests the use of ezetimibe as
a second-line add-on to statin therapy, including in patientswith comor-
bidities or baseline LDL-C ≥ 4.9mmol/L (≥190mg/dL) [70]. Nomajor side
effects have been reported with ezetimibe use [4,70].
5.3.2. Bile acid sequestrants
Bile acid sequestrants (cholestyramine, colestipol and colesevelam
[106])were the ﬁrst class of drugs to show a reduction in ASCVD risk re-
lated to LDL-C lowering [106,107]. When used as a monotherapy, bile
acid sequestrants reduce LDL-C by 18–25% [4]. Addition to a statin pro-
vides an average 10–20% further reduction in LDL-C levels, beyond that
of the statin alone [4] (Table 2). In cases of statin intolerance, clinicians
may wish to consider combining a bile acid sequestrant with ezetimibe
[4]. The 2016 ACC consensus report also highlights their use as an alter-
native to ezetimibe in patients with TG b3.4mmol/L (b300mg/dL) and
baseline LDL-C ≥ 4.9 mmol/L (≥190 mg/dL) [70]. Bile acid sequestrants
can cause gastrointestinal side effects thatmay limit their use. These ad-
verse effects may be reduced by initiating treatment at a low dose and
increasing the dose gradually, and also by ensuring that the patient con-
sumes ample amounts ofﬂuid at the timeof drug administration [4]. Cli-
nicians should also be aware that TG may increase in patients treated
with bile acid sequestrants [4].
5.3.3. Niacin
Niacin monotherapy reduces LDL-C by 15–18% (Table 2) and TG by
20–40%. Niacin also increases HDL-C in a dose-dependent manner by
up to 25% [4]. Extended-release niacin may be used in combination
with statins [4], and produces a larger increase in HDL-C and decrease
in TG than statin alone or statin in combination with ezetimibe [108].
Further reductions (38%) in LDL-C, beyond those of statin/ezetimibe
combination alone, have been reported [90] (Table 2), although other
studies have found no additional reduction [108]. Side effects associated
with niacin include skin reactions, hyperuricaemia and hepatotoxicity
[4] and concerns exist regarding niacin side effects. In the HPS2-
THRIVE study, 25% of patients receiving combined extended release ni-
acin and laropiprant (compared with 17% receiving placebo) stopped
Table 4
The beneﬁcial effects of lifestyle modiﬁcations on lipid levels.
Lifestyle modiﬁcation Effect on lipid levels
Nutrition
↓ trans fats (e.g. margarine, processed foods) ↓LDL-C +++, ↓TG, ↑HDL-C+++
[2,4,21]
↓ saturated fats (e.g. palm or coconut oil,
beef, lamb, processed foods, ghee)
↓LDL-C+++, ↓TG + [2,4,21]
↓ carbohydrates (e.g. wheat ﬂour, white rice,
potato)
↓TG++, ↓VLDL, ↑HDL-C++ [4,21]
↓mono and disaccharides (e.g. sugar-heavy
desserts and drinks)
↓TG+++ [2,4,21], ↑HDL-C+ [4]
↑ ﬁbre (e.g. wholegrain carbohydrates, fruit,
vegetables, nuts and seeds)
↓LDL-C++, ↓TG [2,4,21]
Phytosterols intake ↓LDL-C+++, ↓TG [2,4,21]
n-3 polyunsaturated fats supplements/foods
intake (e.g. oily ﬁsh)
↓TG++ [2,4,21]
Exercise
↑ regular exercise ↓LDL-C+, ↓TG++, ↑HDL-C+++
[4,21]
Body weight
↓ excess weight ↓LDL-C+, ↓TG+++, ↑HDL-C++
[2,4,21]
Other modiﬁcations
Alcohol cessation ↓TG+++ [4,22]
Smoking cessation ↓TG+ [4,21,22], ↑HDL-C + [4]
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol;
TC, total cholesterol; TG, triglyceride; VLDL, very low-density lipoprotein;+++=gener-
al agreement on the effects on lipid levels; ++= less pronounced effects on lipid levels;
weight of evidence/opinion is in favour of efﬁcacy; + = conﬂicting evidence, efﬁcacy is
less well established by evidence/opinion [4].
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testinal, diabetes and musculoskeletal side effects. The treatment was
also associated with increased risk of myopathy in Chinese patients
[109].
5.3.4. PCSK9 inhibitors
Two monoclonal antibodies that inhibit PCSK9 were approved by
the FDA [110] and European Medicines Agency [95,96] in 2015:
alirocumab and evolocumab.When used asmonotherapy, PCSK9 inhib-
itors reduce LDL-C levels by 47–57% [91,92]. PCSK9 inhibitors are more
efﬁcacious than ezetimibe in lowering LDL-C [91,92]. When added to a
statin or ezetimibe, PCSK9 inhibition provides a further 44–75% reduc-
tion in LDL-C, beyond that achieved by the statin or ezetimibe alone
[4,93,95–99] (Table 2). PCSK9 inhibitors should be considered for
high-risk patients in whom LDL-C levels remain higher than the recom-
mended goals despite takingmaximal tolerated doses of a statin [95,96,
111]. PCSK9 inhibitors can also be used in combinationwith other lipid-
lowering agents [2,95,96]. The 2016 ACC consensus document high-
lights the potential of PCSK9 inhibitors as an adjunctive therapy to
statins including when baseline LDL-C ≥ 4.9 mmol/L (≥190 mg/dL),
and also as a potential replacement for statins, including in cases of stat-
in intolerance or of comorbidities [70]. The NLA 2015 guidelines recom-
mend that PCSK9 inhibitors be used as an adjunct to statin therapy in
patients with ASCVD and LDL-C levels ≥2.6 mmol/L (100 mg/dL) or
non-HDL-C levels ≥3.4 mmol/L (130 mg/dL), in high-risk patients with
ASCVD with LDL-C and HDL-C levels that exceed their treatment goals,
and in high- or very high-risk patients who are statin-intolerant [2].
The Canadian Consensus Working Group have also listed PCKS9 inhibi-
tors as a pharmacotherapeutic option in patients with statin intolerance
[112]. To date, no serious adverse effects have been reported with the
use of PCSK9 inhibitors. Minor adverse effects include injection-site re-
actions [113] and respiratory effects [95,96].
Large clinical ASCVD outcomes trials of PCSK9 inhibitors are ongoing
[110,111]. However, there are some preliminary, post-hoc shorter-term
CV data available suggesting that these agents may reduce ASCVD risk
[111]. In a post-hoc analysis comparing the addition of evolocumab to
standard therapy, 1-year ASCVD events were reduced (0.95%, vs 2.18%
for standard therapy alone, p = 0.003) [114]. A post-hoc analysis of a
78-week trial assessing the addition of alirocumab to statin therapy
demonstrated a lower rate of major CV events compared with statin
alone (1.7% vs 3.3%, p= 0.02) [94].
6. Lifestyle modiﬁcations
Lifestyle modiﬁcation is an essential component of themanagement
of patients with disorders of plasma lipids [4,5,21,22]. Information on
lifestyle modiﬁcations should be provided to all patients at moderate
or high risk of ASCVD, whether or not they are receiving pharmacother-
apy [4]. It is critical to encourage adherence to a healthy lifestyle (which
has traditionally been an issue in the Middle East). To this end, struc-
tured programmes are required for long-term effectiveness [4] and on-
going support is known to be valuable in maintaining weight loss [2].
The beneﬁcial effects of lifestyle modiﬁcations on lipid levels are
shown in Table 4.
6.1. Nutrition
There has been aworldwide shift towards amore energy-dense diet,
which contains fewer high-ﬁbre foods and greater levels of processed
foods. This transition is contributing to an increase in obesityworldwide
and is driven by factors including economic growth, urbanisation and
globalisation [115].Many countries in theMiddle East have been under-
going development and urbanisation at a rapid rate over recent years,
and this has been reﬂected in nutrition transition in the region. Food
supply has increased over the last decade inmanyMiddle Eastern coun-
tries [116] and has altered such that an increase in overall daily energyconsumption has occurred. Protein and fat consumption in the Middle
Eastern diet has also increased, including increased consumption of
meat products. A decrease in consumption of cereals, fruit and vegeta-
bles has occurred in richer countries in the region, alongwith a dramatic
increase in fat consumption in some countries and a high sugar intake in
some regions due to local dietary customs [117]. The Western diet,
which is increasing in prevalence in the Middle East, is known to be as-
sociated with several ASCVD risk factors (including high plasma TG and
low HDL-C, MetS, T2DM and obesity) [118,119]. Some traditional Mid-
dle Eastern diets are also linked to plasma lipid disorders. For example,
the Iraniandiet (including high levels of reﬁned grains, potato, hydroge-
nated fats, and broth) has been demonstrated to be signiﬁcantly associ-
ated with low HDL-C and high TG levels [119].
Patients in the Middle East should be advised to modify their diet to
reduce trans fats [2,4,21], saturated fats [2,4,21], carbohydrates [4,21]
and mono- and disaccharides [4], and to increase ﬁbre [2,4,21] and in-
take of phytosterols [2,4,21] and foods/supplements rich in n−3 poly-
unsaturated fats [2,4,21].
6.2. Exercise recommendations
Patients should be advised to participate in regular, moderate-
intensity exercise, aiming for at least 30 min daily [4,21]. Moderate in-
tensity can be considered as aerobic exercise at 40–75% of the patient's
aerobic capacity. Patients aiming to reduce bodyweight can increase ex-
ercise levels gradually up to 250–300min perweek [5]. Regular exercise
has proven beneﬁts on plasma lipid levels (Table 4) and is particularly
important in thosewith obesity,MetS andT2DM [4] (which are all high-
ly prevalent in the Middle East).
6.3. Body weight recommendations
There is a high prevalence of overweight and obesity in the Middle
East, with up to 40% of males and 30% of females being overweight,
and 30% of males and 40% of females being obese [120]. Challenges
exist with respect to the measurement of obesity and its relation to
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BMImay not be as predictive of ASCVD risk in this population compared
withWestern countries [20,51], and that BMI risk thresholds calculated
in European populations may not be appropriate to use in Middle East-
ern populations [121]. Instead, it is thought that values adapted for use
in individuals of a speciﬁc ethnic origin may give a higher prediction of
mortality in upper centiles of BMI [122].
A number of studies suggest that measurements of abdominal obesi-
ty, such as waist circumference (WC) values, may be more appropriate
for use in theMiddle East and that threshold values for abdominal obesi-
ty should be adapted for use inMiddle Eastern populations. For example,
in the INTERHEART Middle East study, abdominal obesity (measured by
waist-to-hip ratio) (but not BMI) was signiﬁcantly associated with the
risk of acute myocardial infarction [20]. However, the IDEA study,
which assessed 168,000 primary care patients in 63 countries, found
that BMI may be more predictive of CVD than WC in Middle Eastern
males [120]. WC thresholds for abdominal obesity have been calculated
in Middle Eastern populations, with a threshold of N78.5 cm for males
and N84.5 cm for females suggested in a study of an Omani Arab popula-
tion [123]. Thresholds have also been calculated in Iran for ASCVD risk
with a threshold of ≥90 cm indicative of patients at risk for ASCVD and
requiring lifestyle modiﬁcations and ≥95 cm indicative of high risk pa-
tients who require immediate intervention [121].
Despite these difﬁculties in determining precise thresholds for over-
weight and obese subjects, it is important that all patients should be ad-
vised to reduce excess body weight [2,4,21] (Table 4).
6.4. Other lifestyle recommendations
Where alcohol is legally available, patients should be advised to keep
intake to a minimum [4] (Table 4). Smoking cessation should also be
recommended to all patients who smoke [4,21,22] (Table 4), including
shisha andwaterpipe tobacco smoking. Smoking prevalence in theMid-
dle East is somewhat variable. A 2012 systematic analysis of surveys and
databases in the region calculated that 52 million people in the Middle
East and North Africa were smokers, with prevalence in Middle Eastern
countries ranging from 8 to 27% [124].
7. Management of underlying conditions
A number of underlying conditions exist that predispose to abnor-
mal plasma lipid levels. Here we review those most pertinent to clini-
cians in the Middle East: metabolic dyslipidaemia, elevated Lp(a),
diabetes mellitus, CKD, FH, human immunodeﬁciency virus (HIV) and
rheumatoid arthritis (RA).
7.1. Patients with high plasma TG and low HDL (metabolic dyslipidaemia)
Patients presenting with high levels of plasma TG and low levels of
HDL-C are common in theMiddle East [9]. This is important as there is in-
creasing evidence that hypertriglyceridaemia is associated with elevated
CVD risk [80]. In patients with mild-to-moderate hypertriglyceridaemia,
lifestyle modiﬁcations alone may be sufﬁcient [28], while statin therapy
should be considered for all patients in whom additional risk factors are
present.
Add-on ﬁbrate (e.g. fenoﬁbrate, bezaﬁbrate, or ciproﬁbrate) therapy
should be considered an option in patients with elevated levels of plas-
ma TG and low levels of HDL-C despite taking statins [22,28]. When
used as an add-on therapy to statins [2], ﬁbrates are associated with a
greater reductions in TG levels, and a greater increase in HDL-C (com-
pared with either used as a monotherapy) [125]. Subgroup analyses of
ﬁbrate trials have consistently demonstrated that ﬁbrates decrease
ASCVD events in those with elevated levels of plasma TG and low levels
of HDL-C [4,126]. Fibrates are generally well tolerated. Gastrointestinal
side effects occur in around 5% of patients and skin rash occurs in
around 2% of patients. Other clinically important side effects aremyopathy (b1% increased risk [127]), cholelithiasis (b1% increased
risk [127]) and increases in liver enzymes (b1%) [4].
In addition to statins, ﬁbrates and lifestyle modiﬁcations, there is
some evidence that n−3 fatty acids may have utility in patients with
high levels of plasma TG and low levels of HDL-C – with up to 25–30%
dose-dependent decreases reported in fasting and post-prandial TGs
[4,28]. Clinical trials are ongoing to further investigate the effects of
n−3 fatty acids on ASCVD risk [128]. PCSK9 inhibitors may also be
of value in this patient population [99,129–132]. Further studies are
ongoing [129].
7.2. Patients with elevated Lp(a)
An elevated Lp(a) level is a causal risk factor for ASCVD [4,26,27]. The
mechanism by which raised levels of Lp(a) increase ASCVD risk is not
known, but may relate to pro-thrombotic/anti-ﬁbrinolytic effects [26].
Few efﬁcacious treatment options exist; niacin lowers Lp(a) levels by
up to 30% [4]. PCSK9 inhibitors may represent a new therapeutic option
in these patients, with Lp(a)-reducing effects seen in post-hoc analyses
of both evolocumab [133] and alirocumab [134] clinical trials. LDL aphe-
resis is considered the most efﬁcacious method to reduce Lp(a) and
should be considered as a treatment option for patients with elevated
Lp(a) [4]. This specialised technique removes LDL and Lp(a) from the
plasma during extracorporeal circulation, once every 1–2 weeks [4,21,
22]. However, LDL apheresis is of limited availability in the Middle
East. Finally, oestrogen and oestrogen replacement therapies also de-
crease Lp(a) by up to 10% [26], therefore the panel suggest that these
may be considered in female patients, if not contraindicated.
7.3. Diabetes mellitus
The Middle East and North Africa region has one of highest diabetes
prevalence rates globally (9–11%), with T2DM predominating [19,135].
In a World Health Organization 2007 report, four of the ﬁve countries
where diabetes was most prevalent were Middle Eastern countries
(United Arab Emirates, Saudi Arabia, Bahrain and Kuwait) [136] and di-
abetes rates are predicted to rise signiﬁcantly in Middle Eastern coun-
tries by 2030 [136,137] (Table 5). A 2015 International Diabetes
Federation Report estimates that over 9% of adults (20–79 years) in
the Middle East and North Africa have diabetes, with over 40% of
these undiagnosed [135]. Seven to 8% of the Middle East and North
Africa population is estimated to suffer from impaired glucose tolerance,
and to be at an increased risk of diabetes [19,135], and MetS prevalence
is approximately 25% [18].
7.3.1. Type 2 diabetes (T2DM)
An elevated level of plasma TG combined with a low level of HDL-C
and an LDL fraction characterised by small dense particles is frequently
encountered in peoplewith T2DM [138,139]. This lipid proﬁle may partly
account for the high ASCVD risk in patients with T2DM [138,139]. Man-
agement of both glucose levels and the metabolic dyslipidaemia is inte-
gral to minimising CVD risk [22], and appropriate glycaemic control
reduces TG levels [28]. The current management of dyslipidaemia and
glycaemic control in T2DM in the Middle East is suboptimal [19,140].
Middle Eastern countries suffer from a high prevalence of other
T2DM risk factors (e.g. obesity) due to changing lifestyles, exercise
levels and diets in recent decades [10,19]. Therefore, to manage plasma
lipids in patients with T2DM, lifestyle modiﬁcations are essential for all
patients [4,139,141], and individualised dietary advice is important [4].
For all patients, statin therapy should be considered and individualised,
including with respect to age and LDL-C levels [4,5]. In patients aged
40–75 years with LDL-C ≥ 70 mg/dL, moderate-intensity statin therapy
should be initiated [5]. The panel also recommends that statins should
be initiated in patients b40 years of age if T2DM duration ≥10 years.
The UK NICE guidelines recommend statin initiation in patients with
T2DMwith a ≥10% 10-year risk of developing ASCVD [142].
Table 5
Predicted prevalence of diabetes in Middle Eastern countries in 2030, compared with
those reported in 2000 [137].
Country 2000 2030
Arab World 7,814,000 22,157,000
Bahrain 37,000 99,000
Egypt 2,623,000 6,726,000
Iraq 668,000 2,009,000
Jordan 195,000 680,000
Kuwait 104,000 319,000
Lebanon 146,000 378,000
Oman 113,000 343,000
Qatar 38,000 88,000
Saudi Arabia 890,000 2,523,000
Syria 627,000 2,313,000
United Arab Emirates 350,000 684,000
Yemen 327,000 1,286,000
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may be added. Ezetimibe, or alternatively bile acid sequestrants, can
be added to statin therapy in patients aged 40–75 years with LDL-C
1.8–4.9 mmol/L (70–189 mg/dL) [70]. Addition of ﬁbrates may be ben-
eﬁcial in some groups. Fibrates have been found to reduce ASCVD event
rates in T2DM patients with elevated plasma TG and low HDL-C levels
[126,143]. Data regarding the beneﬁcial effects of ﬁbrates on ASCVD
risk in diabetic patients with normal levels of plasma TG and HDL-C
have been disappointing [143].
As an alternative to ﬁbrates, colesevelam (a bile acid sequestrant)
may be considered as an add-on to statin therapy as it has been
shown to improve HbA1c levels in T2DM [144,145]; however, it is not
widely available in the region. PCSK9 inhibitors may also be considered,
as these are efﬁcacious in patients with T2DM, with LDL-C reductions of
approximately 60% [146–148], which is much greater than observed
with ezetimibe [146]. The American Diabetes Association recommends
that PCSK9 inhibitors are considered as an adjunct to statin therapy in
diabetic patients with high risk for ASCVD who have not attained their
LDL-C goals, and as an option in those intolerant to statins [149]. Fur-
thermore, niacin could be considered in those patients for whom
ﬁbrates are contraindicated, although it may worsen glycaemic control
[4,109,150].
7.3.2. Type 1 diabetes
Type 1 diabetes is associated with increased CVD risk [151]. Patients
typically have lower than normal levels of TG and LDL-C andhigher than
normal levels of HDL-C, thought to be due to insulin treatment, with
atherogenic changes in particle composition. Statins are the ﬁrst-line
treatment for managing plasma lipids in patients with type 1 diabetes,
with an LDL-C goal of 30% reduction regardless of baseline LDL-C levels
[4]; the panel recommends a goal of 50% reduction in LDL-C in patients
with type 1 diabetes if established ASCVD is also present.
7.4. Chronic kidney disease (CKD)
CKD is amajor risk factor for ASCVD [152,153] and is associatedwith
an 8 to 10-fold increase in cardiovascularmortality [136]. Abnormalities
of plasma lipids are common in people with CKD [23], including in-
creased TGandnon-HDL-C levels, and decreased levels ofHDL-C [4]. Ab-
normalities of plasma lipids increase with worsening glomerular
ﬁltration rate (GFR) [4] as do CKD-related ASCVD risk factors, such as in-
ﬂammation, oxidative stress and vascular calciﬁcation [154]. The level of
vascular calciﬁcation in CKD patients is also predictive of ASCVD risk
[155–158] and is increased in patients with concomitant diabetes and
CKD [158–160]. These CKD-related ASCVD risk factors are distinct
from those in the general population [154]. All newly diagnosed CKD
patients should be screened for plasma lipid disorders [23]. Other
ASCVD risk factors present in patients with CKD include obesity, diabe-
tes and hypertension [153], which are all prevalent in Middle Easterncountries [16,136]. ASCVD can be complex in CKD patients, and is
often underdiagnosed and undertreated [153].
The global prevalence of CKD is 5–7% [152] –with higher prevalence
rates in developing countries [152] – and is rapidly increasing world-
wide [4]. Accurate data and large epidemiological studies on the preva-
lence of CKD in theMiddle East are somewhat lacking [136,161,162] and
prevalence is likely under-reported [136]. There may also be a popula-
tion of undiagnosed and untreated patients [136]. Nevertheless, some
data are available, which suggest that the incidence in the Middle East
may be higher than global levels. A large (n=10,748) Turkish study re-
ported CKD prevalence of 16% [163]. In the same population the preva-
lence of hypertension, diabetes, dyslipidaemia, obesity, and MetS were
33%, 13%, 76%, 20%, and 31% respectively [163]. Large (n N 10,000)
Iranian studies estimate CKD prevalence to be approximately 11–13%
[164,165]. Another Iranian study (n=3313) reported incidence density
rates 285 and 133 per 10,000 person-year (women and men, respec-
tively) [166], suggesting that N2% population develops CKD each year.
End-stage renal disease (ESRD) incidence is estimated at 100–140
cases permillion in theMiddle East [161], and thismay be increasing ac-
cording to data from one country (Saudi Arabia) [162]. A literature re-
view of data from ten Middle Eastern countries estimated average
incidence rates of ESRD as 93 patients permillion,with an average prev-
alence of 352 patients per million [167].
While LDL-C is not as predictive of ASCVD risk in CKD patients as in
the rest of population [168], LDL-C lowering by the combination of sim-
vastatin plus ezetimibe has been shown to reduce ASCVD risk [23,169].
However, there is no evidence to date that statins reduce CVD risk in pa-
tients receiving dialysis. The choice of treatment should be based on GFR
[4,23] andwhere possible, it is recommended that prescribed pharmaco-
therapies should be those cleared by hepatic routes [4]. It is also impor-
tant to note that CKD patients may be receiving multiple medications,
therefore the potential for drug–drug interactions with lipid-lowering
medications should be carefully considered (e.g. many statins undergo
signiﬁcant cytochrome P450 metabolism [4,170]). The recommended
treatments for dyslipidaemia in patients with CKD are outlined in
Table 6 and statin doses in Table 7. These recommendations are aligned
with the 2013 KDIGO clinical practice guideline for lipid management in
CKD [23].
7.5. Familial hypercholesterolaemia
FH confers a greatly increased risk of ASCVD [4,68,171]. It is
characterised by high LDL-C levels [4,29,68,171]. If untreated, FH results
in premature ASCVD and premature death [4,29,68,171]. FH is inherited
in an autosomal dominantmanner, and canbe either heterozygous or ho-
mozygous (with homozygous being the more severe form) [4,68,171].
Heterozygous FH is the more common form, affecting 1 in 250 peo-
ple in European populations [172,173], with homozygous FH affecting 1
in approximately 300,000 people [174]. Both heterozygous and homo-
zygous FH are important in theMiddle East due to a higher level of con-
sanguineous marriages [29,30]. Surprisingly, however, FH prevalence
data in theMiddle East are lacking. Nevertheless, extrapolation of global
data and the local data available suggest that rates of homozygous FH
are higher in the Middle East than in the West [29].
FH is underdiagnosed in the Middle East [29,30]. Diagnosis of FH
should include a number of components, including the assessment of
LDL-C levels, xanthomas and family history. Useful diagnostic criteria
that encompass these various elements are available, including the
WHO criteria [175], Dutch criteria [176] and Simon-Broome criteria
[177], which has been used successfully in an Omani Arab population
[178]. Adulthood LDL-C levels in untreated FH are typically 5–10
mmol/L (200–400 mg/dL) in heterozygous FH [4] and N13 mmol/L
(500 mg/dL) in homozygous FH, although levels can be lower [29].
Xanthomas may be present in patients with homozygous FH (although
not in every case) [4,29] and tendon xanthomatas may present in cases
of heterozygous FH [4]. To differentiate FH from other conditionswhere
Table 6
Recommendations for managing plasma lipids in patients with chronic kidney disease [23].
Patient type (adults) Treatment recommendation
≥50 years
eGFR b60 mL/min/1.73 m2
Not treated with chronic dialysis or kidney transplantation
(GFR categories G3a–G5)
Statin or statin/ezetimibe
≥50 years
CKD and eGFR N 60 mL/min/1.73 m2
(GFR categories G1-G2)
Statin
18–49 years
CKD
Not treated with chronic dialysis or kidney transplantation
One or more of following present
• known coronary disease (myocardial infarction or coronary revascularisation)
• diabetes mellitus
• prior ischaemic stroke
• estimated 10-year incidence of coronary death or non-fatal myocardial infarction N10%
Statin
Kidney transplant recipient Statin
Dialysis-dependent CKD Do not initiate statin (if already receiving at time of dialysis initiation, continue)
CKD and high TG Lifestyle modiﬁcations
CKD, chronic kidney disease; eGFR, estimated glomerular ﬁltration rate; GFR, glomerular ﬁltration rate; TG, triglyceride.
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ily history is critical [4,29,178] and genetic testing should be considered
(in the case of homozygous FH in particular) [29]. However, genetic
testing is of limited availability in the Middle East currently [29]. Pa-
tients with FH should also be screened for other potential underlying
dyslipidaemia risk factors (e.g. diabetes) [29].
In addition to lifestyle modiﬁcations [4,178], statins should be ﬁrst-
line treatment for dyslipidaemia in FH [4,29]. However, even themost po-
tent statins may be insufﬁcient to achieve recommended LDL-C levels [4,
29,178]. In such cases, the addition of another medication (e.g. ezetimibe
[4,21], a PCSK9 inhibitor [2,95,96,148]), or bile acid sequestrants [4]
should be considered; the 2016 ACC consensus statement recommends
that a PCSK9 inhibitor may be considered as a ﬁrst-line adjunct [70]. In
the case of homozygous FH, which is a complex disorder that should be
treated under the guidance of a specialist and include careful medication
monitoring, LDL apheresis should be used alongside statin therapywhere
available [4]. The panel recommend that the LDL-C time-averaged mean
for apheresis in homozygous FH patients should be b2.6 mmol/L (b100
mg/dL). The microsomal transfer protein inhibitor lomitapide is also
now available in the Middle East and is indicated as an adjunct to other
pharmacotherapies in the treatment of homozygous FH [179,180].
Lomitapide reduces LDL-C by up to 50% and TG by 45% when adminis-
tered as an adjunct therapy [181]. In some countries, the oligonucleotide
mipomersen [182] is also approved as an add-on to statins for the treat-
ment of homozygous FH. Thismedication is associatedwith an incremen-
tal LDL-C reduction of 25–36% [183,184]. Evolocumab can also be
considered as an adjunct therapy in homozygous FH patients [96,185,
186], and is efﬁcacious in LDL-receptor-defective patients [185].Table 7
Recommended statin doses (mg/d) in adults with chronic kidney disease [23].
Statin eGFR
G1–G2
eGFR G3a–G5, including patients
on dialysis or with a kidney
transplant
Lovastatin GP ns
Fluvastatin GP 80
Atorvastatin GP 20
Rosuvastatin GP 10
Simvastatin/ezetimibe GP 20/10
Pravastatin GP 40
Simvastatin GP 40
Pitavastatin GP 2
CKD, chronic kidney disease; eGFR, estimated glomerular ﬁltration rate; GP, general pop-
ulation; ns, not studied.7.6. HIV
HIV is associatedwith an increased prevalence of CVD, thought to be
due in part to HIV-associated inﬂammatory and immune activity and in
some cases related to antiretroviral therapy. HIV should however be
considered a CVD risk factor and patient education on this topic is im-
portant. In general, patients with HIV and plasma lipid disorders should
be treated with pharmacotherapy in the sameway as other patients, al-
though consideration should be given to the possibility of drug–drug
interactions [2].
7.7. Rheumatoid arthritis (RA)
The systemic inﬂammation present in RA confers an increased risk
of CVD [2,187] and CVD is the leading cause of death in RA patients
[188]. Lipid levels vary depending on RA treatment and the level of in-
ﬂammation present, and can be lower than those in the general popula-
tion despite an overall increased CVD risk. Some RA medications (e.g.
methotrexate) may undergo drug–drug interactions with lipid-
lowering drugs. These should be considered when selecting treatment
and monitoring may be required [2].
8. Management of special populations
Sub-populations of patients with plasma lipid disorders require spe-
cial management: here we provide guidance on the management of
plasma lipids in pregnancy and lactation, and in children.
8.1. Pregnancy and breastfeeding
Lipid levels increase during pregnancy, peaking as the woman ap-
proaches term. In a ‘normal’ pregnancy neither TC and TG levels should
exceed 250 mg/dL; if these levels are exceeded this may indicate a pre-
pregnancy plasma lipid disorder, whichmay lead to an increased risk of
obstetrical and foetal complications (hypertriglyceridaemia may also
indicate undiagnosed pre-pregnancy diabetes). This pregnancy-related
increase in lipid levels represents an additional risk factor for CVD in pa-
tients with FH. If pre-pregnancy lipid levels are unknown, evaluation
may be incorporated into routine pregnancy blood tests and conducted
again six weeks post-natally [2].
In general, women receiving lipid-loweringmedication,with the ex-
ception of bile acid sequestrants, are advised to stop pharmacotherapy
in preparation for, and during, pregnancy [70], although preliminary
Box 5
Summary of recommendations.
Screening
Every five years in patients≥20 years old [22].
In all patients with T2DM [4,22]; arterial hypertension [4]; manifest ASCVD [4,22]; central obesity [4]; chronic inflammatory autoimmune disease
[4]; CKD [4,22]; family history of ASCVD [4].
Offspring of patients with severe plasma lipid disorders (e.g. FH) [4].
Screening endpoints
LDL-C, TC, TG, HDL-C, non-HDL-C, Lp(a) (in high-risk patients) [4]; family history [2]; genetic testing (dependent on family history) [4];
ASCVD risk scoring system [4].
Primary treatment goals
LDL-C
High-risk patients: 50% reduction AND b1.8 mmol/L (b70 mg/dL) (after 50% reduction achieved).
Moderate-risk patients: 30% reduction AND b2.6 mmol/L (b100 mg/dL) (after 30% reduction achieved).
Non-HDL-C
0.8 mmol/L (30 mg/dL) higher than LDL-C target [4,71].
Treatment
Pharmacotherapy
First-line [4,5,21,22]: statins.
Second-line/adjuncts [4,21,70]: cholesterol absorption inhibitors (ezetimibe); bile acid sequestrants (cholestyramine, colestipol and
colesevelam); niacin; PCSK9 inhibitors.
Lifestyle modifications
↓ trans fats [2,4,21], saturated fats [2,4,21], carbohydrates [4,21] and mono- and disaccharides [4].
↑ fibre [2,4,21] and intake of phytosterols [2,4,21] and foods/supplements rich in n−3 polyunsaturated fats [2,4,21].
Regular, moderate-intensity exercise (30 min daily) [4,21]; ↓ excess body weight [2,4,21].
Alcohol (where legally available) kept to a minimum [4]; smoking cessation [4,21,22].
Patient with underlying conditions
Metabolic dyslipidaemia: mild-to-moderate: lifestyle modifications [28]. Additional risk factors: consider statin therapy. If dyslipidaemia persists:
add-on fibrates [22,28]. n−3 fatty acids and PCKS9 inhibitors may be useful [4,28,99,129–132] (studies ongoing [128,129]).
Elevated Lp(a): few efficacious treatments. LDL [4]; niacin [4]; possibly PCSK9 inhibitors [133,134]; oestrogen and oestrogen replacement
[26] in female patients, if not contraindicated.
T2DM: Lifestyle modifications [4,139,141] and individualised dietary advice [4]. Statins [4]: moderate-intensity [5] in patients aged 40–75 years
with LDL-C≥ 70 mg/dL. Individualise with respect to age and LDL-C levels in other patients [5]. Initiate statins in patients b40 years of age if
T2DM duration≥10 years.
Add-on therapies (if statin alone not efficacious): ezetimibe, or bile acid sequestrants, in patients aged 40–75 years with LDL-C 1.8–4.9 mmol/L
(70–189 mg/dL) [70]; fibrates (in patients with elevated plasma TG and low HDL-C levels) [126,143]; colesevelam as an alternative to fibrates
[144,145]; PCSK9 inhibitors may also be considered [146,147]; Niacin could be considered if fibrates contraindicated; may worsen glycaemic
control [4,109,150].
T1DM: first-line pharmacotherapy: statins [4].
CKD [23]: dialysis-dependent: do not initiate statins. High TG: lifestyle modifications. Other CKD patients: statins.≥50 years, GFR
categories G3a–G5: also consider add-on ezetimibe.
FH: Lifestyle modifications [4,178]; statins are first-line pharmacotherapy [4,29]. Add-on therapies (if statin alone not efficacious): ezetimibe
[4,21], PCSK9 inhibitor [95,96]), or bile acid sequestrant [4]. Also lomitapide for homozygous FH [179,180]. In some countries, mipomersen
[182] for homozygous FH.
HIV: consider drug–drug interactions [2].
RA: consider drug–drug interactions, monitoring may be required [2].
Special populations
Pregnancy and breastfeeding: lifestyle modifications; stop pharmacotherapy (with the exception of bile acid sequestrants) in preparation for,
and during, pregnancy [70].
Hypertriglyceridaemia (≥500 mg/dL): n-fatty acids and/or fibrates (fenofibrate or gemfibrozil) into the second trimester, based on clinical
judgement [2,191].
FH: colesevelam and LDL apheresis [2].
Pharmacotherapy and breastfeeding: FH: colesevelam [2,191,192]; hypertriglyceridaemia: pharmacotherapy [2,191,192]; statin and ezetimibe
may be resumed after completion of breastfeeding [70].
Children:Monitoring of lipid levels and ASCVD risk factors [2]; lifestyle modifications [2]; avoid lipid-lowering pharmacotherapy, except in
FH [4].
ASCVD, atherosclerotic cardiovascular disease; CKD, chronic kidney disease; FH, familial hypercholesterolaemia; HDL-C, high-density lipoprotein
cholesterol; HIV, human immunodeficiency virus; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein(a); non-HDL-C, non-high-density lipo-
protein cholesterol; RA, rheumatoid arthritis; TC, total cholesterol; TG, triglyceride; T1DM, type 1 diabetesmellitus; T2DM, type 2 diabetesmellitus;
PCSK9, proprotein convertase subtilisin/kexin type.
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the use of lipid-loweringmedications in pregnancy from human studies
are somewhat lacking and animal studies have elicited mixed data [2,
190]. The safety of PCSK9 inhibitors during pregnancy has not yet
been determined [2]. Lifestyle modiﬁcations should be continued
throughout pregnancy.
8.1.1. Pharmacotherapy in pregnancy: special circumstances
Hypertriglyceridaemia (≥500 mg/dL) may be treated with n-fatty
acids and/or ﬁbrates (fenoﬁbrate or gemﬁbrozil) into the second trimes-
ter, based on clinical judgement [2,191].Womenwith FHmay be treated
with colesevelam and LDL apheresis during pregnancy. In women with
gestational diabetes or pre-existing diabetes good glycaemic control is
also critical [2]. Currently no safety and efﬁcacy data are available
regarding the use of mipomersen [70] or PCSK9 inhibitors in pregnancy
[70,95,96].
8.1.2. Pharmacotherapy and breastfeeding
Breastfeeding women should continue with lifestyle modiﬁcations.
Those with FH may continue colesevelam. Medications for hypertri-
glyceridaemia may also be continued. Breastfeeding, including duration
of lactation, has a beneﬁcial effect on future ASCVD risk [2,191,192]. Stat-
in and ezetimibemay be resumed after completion of breastfeeding [70].
Currently, safety and efﬁcacy data are not available regarding the use of
PCSK9 inhibitors in breastfeeding [95,96].
8.2. Children
With the exception of conditions such as FH, ASCVD is rare in child-
hood [2,4]. Nevertheless, accumulation of ASCVD risk factors can occur,
for example obesity and insulin resistance [2], and conditions such as di-
abetesmellitus and Kawasaki disease can lead to childhood plasma lipid
disorders [2]. Therefore, in children with these conditions, monitoring
of lipid levels and ASCVD risk factors and management with lifestyle
modiﬁcations are integral to improved outcomes in adulthood [2].
Lipid-lowering pharmacotherapy should generally be avoided in chil-
dren with increased lipids, with the exception of those with FH [4].
9. Future directions
The recommendations presented here represent the ﬁrst set of clini-
cal recommendations for the management of plasma lipid disorders in
the Middle East (summarised in Box 5). To continue to improve patient
management in the region there is a need for further research in the
management of disorders of plasma lipids in the Middle East. Such re-
search should focus on: the development of a region-speciﬁc risk scoring
system for calculating cardiovascular risk; incorporating a comprehen-
sive and cost-effective FH screening program in the region that includes
assessment of family history for all patients and routine screening of chil-
dren at risk of FH; large and accurate regional epidemiological studies of
plasma lipid disorders – particularly metabolic dyslipidaemia, as it is the
most prevalent form of lipid disorder in the region – and FH; and devel-
oping increased patient awareness of, and adherence to, lifestyle advice
andmodiﬁcations. Additionally, as new treatments continue to be exam-
ined (e.g. long-term CV outcome trials with PCSK9 inhibitors) and devel-
oped (e.g. microsomal transfer protein inhibitors [193,194]), there will
be a need to update the current recommendations at an appropriate
time point in the future. Finally, there is a need for lipid clinic networks
and regional lipid societies in theMiddle East to develop lipid education-
al programs to improve the awareness of lipid disorders among physi-
cians, allied health professionals, patients and the public.
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